Effect of recombinant human interferon alpha B/D (rHu-IFN-alpha B/D) in combination with acyclovir in experimental HSV-1 encephalitis.
The efficacy of recombinant human interferon alpha B/D in experimental HSV-1 encephalitis was investigated in the murine system. Recombinant Hu-IFN-alpha B/D significantly reduced the mortality in a mouse encephalitis model (about 30%, P = 0.021), whereas natural mouse interferon was inactive. Combination of acyclovir with Hu-IFN-alpha B/D had an additive effect.
Wintergerst
U
U
Department of Pediatrics, University of Munich, Germany.
Gangemi
J D
JD
Whitley
R J
RJ
Chatterjee
S
S
Kern
E R
ER
D000212:Acyclovir / Q000627:therapeutic use*; D000818:Animals; D000998:Antiviral Agents / Q000627:therapeutic use*; D004195:Disease Models, Animal; D004359:Drug Therapy, Combination; D020803:Encephalitis, Herpes Simplex / Q000188:drug therapy*; D018259:Herpesvirus 1, Human; D006801:Humans; D007370:Interferon Type I / Q000627:therapeutic use*; D051379:Mice; D011994:Recombinant Proteins
D000998:Antiviral Agents; D007370:Interferon Type I; D011994:Recombinant Proteins; D000212:Acyclovir